Iodixanol

Generic Name: Iodixanol

Brand Names: Visipaque, Visipaque 270, Visipaque 320

Drug Type: Small Molecule

Chemical Formula: C_₃₅H_₄₄I_₆N_₆O_₁₅

CAS Number: 92339-11-2

Unique Ingredient Identifier: HW8W27HTXX

Background: Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.

Indication: Iodixanol is a contrast agent during coronary angiography.

Clinical Trials

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Ioxaglate
Drug: Iodixanol
Drug: Bivalirudin

First Posted Date: 2013-05-08

Last Posted Date: 2016-04-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 100

Registration Number: NCT01848899

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction

Phase 4

Conditions: Kidney Failure, Chronic

Interventions: Drug: iodixanol
Drug: iopromide

First Posted Date: 2012-04-18

Last Posted Date: 2013-10-16

Lead Sponsor: Yong Huo

Target Recruit Count: 200

Registration Number: NCT01580046

Locations: 🇨🇳
The First Affiliated Hospital Of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Pla Navy General Hospital, Beijing, China

and more 16 locations

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

Phase 4

Completed

Conditions: Drug Safety

Interventions: Drug: Iopamidol
Drug: Iodixanol

First Posted Date: 2011-11-21

Last Posted Date: 2014-06-11

Lead Sponsor: GE Healthcare

Target Recruit Count: 255

Registration Number: NCT01475097

Locations: 🇺🇸
GE Healthcare, Princeton, New Jersey, United States

Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients

Phase 4

Terminated

Conditions: Chronic Renal Disease

Interventions: Drug: Iopamidol injection 76%
Drug: iodixanol

First Posted Date: 2011-07-26

Last Posted Date: 2013-08-28

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 204

Registration Number: NCT01402219

Locations: 🇨🇳
Guangdong Cardiovascular Institute,Guangdong General Hospital, Guangzhou, Guangdong, China

Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

Phase 4

Completed

Conditions: Patient Comfort and Safety

Interventions: Drug: Iodixanol
Drug: Iopamidol

First Posted Date: 2011-06-20

Last Posted Date: 2013-12-19

Lead Sponsor: GE Healthcare

Target Recruit Count: 304

Registration Number: NCT01376089

Locations: 🇺🇸
GE Healthcare, Princeton, New Jersey, United States

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Terminated

Conditions: Pancreatic Cancer

First Posted Date: 2011-03-30

Last Posted Date: 2016-07-01

Lead Sponsor: Stanford University

Target Recruit Count: 6

Registration Number: NCT01326364

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Not Applicable

Terminated

Conditions: Lung Cancer Small Cell Lung Cancer (SCLC)
Lung Cancer Non-Small Cell Cancer (NSCLC)
Lung Cancer
Mesothelioma

Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT)
Radiation: Computed Tomography (CT)
Device: Cyberknife
Device: Trilogy
Device: True Beam
Drug: Iohexol
Drug: Iodixanol

First Posted Date: 2010-08-25

Last Posted Date: 2018-04-17

Lead Sponsor: Stanford University

Target Recruit Count: 12

Registration Number: NCT01188486

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

DynaCT in Preoperative Imaging Before Insertion of Stentgraft

Not Applicable

Completed

Conditions: Abdominal Aortic Aneurysm

Interventions: Radiation: DynaCT
Drug: Iodixanol

First Posted Date: 2010-06-17

Last Posted Date: 2017-01-18

Lead Sponsor: Norwegian University of Science and Technology

Target Recruit Count: 20

Registration Number: NCT01146639

Locations: 🇳🇴
St Olavs Hospital, Operating Room of the Future., Trondheim, Norway

Kidney Damage In Patients With Severe Fall In eGFR

Phase 4

Terminated

Conditions: Coronary Artery Stenosis

Interventions: Drug: Iopamidol 370
Drug: Iodixanol 320

First Posted Date: 2010-06-04

Last Posted Date: 2014-03-17

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 15

Registration Number: NCT01136915

Locations: 🇨🇦
Institu De Cardiologie De Montreal, Montreal, Quebec, Canada

Kidney Damage in Patients With Moderate Fall in eGFR

Phase 4

Completed

Conditions: Coronary Artery Stenosis

Interventions: Drug: Iodixanol-320
Drug: Iopamidol

First Posted Date: 2010-06-04

Last Posted Date: 2020-11-04

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 57

Registration Number: NCT01136876

Locations: 🇺🇸
UMDNJ - RWJ Medical School, New Brunswick, New Jersey, United States
🇨🇦
Montreal Heart Institute, Montréal, Quebec, Canada
🇺🇸
The Institute for Clinical Research at Holy Name Medical Center, Teaneck, New Jersey, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy